Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults

Abstract

This paper described the Guideline for Diagnosis and Management of Hyperlipidemias for Prevention of Atherosclerosis proposed by The Japan Atherosclerosis Society (JAS) Guideline Investigating Committee (1,995-2,000) under the auspices of the JAS Board of Directors. 1) The guideline defines the diagnostic criteria for serum total cholesterol (Table 1), LDL-cholesterol (Table 1), triglycerides (Table 4) and HDL-cholesterol (Table 7). It also indicates the desirable range (Table 1), the initiation levels of management (Table 2) and the target levels of treatment (Table 2) for total and LDL-cholesterol. 2) Though both total and LDL-cholesterol are shown as atherogenic parameter in the guideline, the use of LDL-cholesterol, rather than total cholesterol, is encouraged in daily medical practice and lipid-related studies, because LDL-cholesterol is more closely related to atherosclerosis. 3) Elevated triglycerides and low HDL-cholesterol are included in the risk factors, since no sufficient data have been accumulated to formulate the guideline for these two lipid disorders. 4) Emphasis is laid on evaluation of risk factors of each subject before starting any kind of treatment (Table 2). 5) This guideline is applied solely for adults (age 20-64). Lipid abnormalities in children or the youth under age 19, and the elderly with an age over 65 have to be evaluated by their own standard. 6) This part of the guideline gives only the diagnostic aspects of hyperlipidemias. The part of management and treatment will follow in the second section of the guideline that will be published in future.

The Relationship Between Low-Density Lipoprotein Cholesterol Levels and the Incidence of Cardiovascular Disease in High-Risk Patients Treated With Pravastatin

“…32) Therefore, these fi ndings are consistent with the LDL-C target for primary prevention recommended by the 2007 JAS guideline. 14) However, the effi cacy of LDL-C lowering for stroke prevention and target levels of LDL-C for coronary artery disease prevention in the Japanese population, especially in high-risk patients, should be further investigated.…”

Comparative Study of Atherosclerotic Parameters in Mongolian and Japanese Patients with Hypertension and Diabetes Mellitus

“…This study was approved by the Ethics Committee of Jichi Medical University and the Mongolian Ministry of Health, and each patient gave their informed consent. Initially, adult outpatients (≥ 20 years of age) with HT and DM, without a medical history of CVD and without serum levels of ≥ 220 mg/dL in total cholesterol (T-Cho) and ≥ 150 mg/dL in triglyceride (TG) 13) , were consecutively recruited from a random invitation to participate in the present study. HT was defined as ≥ 140 mmHg systolic blood pressure (SBP) and/or ≥ 90 mmHg diastolic blood pressure (DBP) or the use of drugs against HT 14) .…”

Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension

“…A diagnosis of hyperlipidemia required a serum total cholesterol level of X5.69 mmol/l and/or a serum triglyceride level of X1.69 mmol/l or the use of lipid-lowering drugs, according to the Japan Atherosclerosis Society guidelines. 14 All patients had taken antihypertensive drugs for at least 1 year (average, 12 years). One hundred and ninety-five patients (72%) were treated with Ca channel blockers, 140 (51%) with renin angiotensin system inhibitors (i.e., angiotensin II receptor blockers and angiotensin converting enzyme inhibitors), 82 (30%) with b-blockers, 53 (19%) with diuretics and 29 (11%) with other classes of agents.…”